PMID- 11842276
OWN - NLM
STAT- MEDLINE
DCOM- 20020702
LR  - 20171101
IS  - 0012-2823 (Print)
IS  - 0012-2823 (Linking)
VI  - 64
IP  - 4
DP  - 2001
TI  - Effects of very long (up to 10 years) proton pump blockade on human gastric 
      mucosa.
PG  - 205-13
AB  - BACKGROUND: Long-term use of proton pump inhibitors (PPI) has been reported to 
      worsen oxyntic mucosa gastritis and the resulting gland atrophy has been 
      considered a potential risk factor for neoplastic changes in the gastric mucosa. 
      AIMS: The present study examines the effect of extended continuous PPI treatment 
      for up to 10 years on the exocrine and endocrine stomach of patients with 
      acid-related diseases of the upper GI tract. METHODS: Biopsies from the antral 
      and oxyntic mucosa taken at regular time intervals were examined for gastritis, 
      atrophy, intestinal metaplasia, Helicobacter pylori and argyrophil cells and 
      correlated to serum gastrin levels. RESULTS: A general amelioration of antral 
      gastritis without relevant changes of atrophy or intestinal metaplasia, 
      contrasted with the worsening of gastritis and gland atrophy seen in the oxyntic 
      mucosa of reflux esophagitis (but not gastric or duodenal ulcer) patients in the 
      presence of H. pylori infection. In association with PPI- induced 
      hypergastrinemia, argyrophil cell hyperplasia (but not dysplasia or neoplasia) 
      developed in the oxyntic mucosa. CONCLUSION: The present results outline the 
      milder pretreatment pattern and higher proneness to PPI-related, H. 
      pylori-restricted worsening of oxyntic mucosa gastritis in reflux esophagitis 
      compared to gastric ulcer or duodenal ulcer patients. In addition, they confirm a 
      substantial safety of long-term PPI therapy as concerns neoplastic changes in the 
      exocrine and endocrine human stomach.
CI  - Copyright 2002 S. Karger AG, Basel
FAU - Lamberts, R
AU  - Lamberts R
AD  - Department of Internal Medicine, Division of Gastroenterology, University of 
      Tubingen, Germany. ReginaLamberts@aol.com
FAU - Brunner, G
AU  - Brunner G
FAU - Solcia, E
AU  - Solcia E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Digestion
JT  - Digestion
JID - 0150472
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Proton Pump Inhibitors)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Ulcer Agents/administration & dosage/*adverse effects
MH  - Enzyme Inhibitors/administration & dosage/*adverse effects
MH  - Female
MH  - Gastric Mucosa/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Omeprazole/administration & dosage/*adverse effects
MH  - *Proton Pump Inhibitors
MH  - Risk Factors
MH  - Stomach Neoplasms/chemically induced
MH  - Time Factors
EDAT- 2002/02/14 10:00
MHDA- 2002/07/03 10:01
CRDT- 2002/02/14 10:00
PHST- 2002/02/14 10:00 [pubmed]
PHST- 2002/07/03 10:01 [medline]
PHST- 2002/02/14 10:00 [entrez]
AID - 48863 [pii]
AID - 10.1159/000048863 [doi]
PST - ppublish
SO  - Digestion. 2001;64(4):205-13. doi: 10.1159/000048863.